558 related articles for article (PubMed ID: 34709727)
21. A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins.
May DG; Martin-Sancho L; Anschau V; Liu S; Chrisopulos RJ; Scott KL; Halfmann CT; Díaz Peña R; Pratt D; Campos AR; Roux KJ
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337019
[TBL] [Abstract][Full Text] [Related]
22. Current Perspective of Antiviral Strategies against COVID-19.
Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
[TBL] [Abstract][Full Text] [Related]
23. Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2.
Shahid M; Shahzad-Ul-Hussan S
J Struct Biol; 2021 Mar; 213(1):107690. PubMed ID: 33383190
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 infection remodels the host protein thermal stability landscape.
Selkrig J; Stanifer M; Mateus A; Mitosch K; Barrio-Hernandez I; Rettel M; Kim H; Voogdt CGP; Walch P; Kee C; Kurzawa N; Stein F; Potel C; Jarzab A; Kuster B; Bartenschlager R; Boulant S; Beltrao P; Typas A; Savitski MM
Mol Syst Biol; 2021 Feb; 17(2):e10188. PubMed ID: 33590968
[TBL] [Abstract][Full Text] [Related]
25. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
26. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.
Nguyen LC; Yang D; Nicolaescu V; Best TJ; Gula H; Saxena D; Gabbard JD; Chen SN; Ohtsuki T; Friesen JB; Drayman N; Mohamed A; Dann C; Silva D; Robinson-Mailman L; Valdespino A; Stock L; Suárez E; Jones KA; Azizi SA; Demarco JK; Severson WE; Anderson CD; Millis JM; Dickinson BC; Tay S; Oakes SA; Pauli GF; Palmer KE; ; Meltzer DO; Randall G; Rosner MR
Sci Adv; 2022 Feb; 8(8):eabi6110. PubMed ID: 35050692
[TBL] [Abstract][Full Text] [Related]
27. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
Fiscon G; Conte F; Farina L; Paci P
PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
[TBL] [Abstract][Full Text] [Related]
28. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.
Rajarshi K; Khan R; Singh MK; Ranjan T; Ray S; Ray S
Gene; 2021 Feb; 768():145313. PubMed ID: 33220345
[TBL] [Abstract][Full Text] [Related]
29. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
30. Interactomes of SARS-CoV-2 and human coronaviruses reveal host factors potentially affecting pathogenesis.
Chen Z; Wang C; Feng X; Nie L; Tang M; Zhang H; Xiong Y; Swisher SK; Srivastava M; Chen J
EMBO J; 2021 Sep; 40(17):e107776. PubMed ID: 34232536
[TBL] [Abstract][Full Text] [Related]
31. Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches.
Ahsan N; Rao RSP; Wilson RS; Punyamurtula U; Salvato F; Petersen M; Ahmed MK; Abid MR; Verburgt JC; Kihara D; Yang Z; Fornelli L; Foster SB; Ramratnam B
Proteomics; 2021 May; 21(10):e2000279. PubMed ID: 33860983
[TBL] [Abstract][Full Text] [Related]
32. Proteomic Approaches to Study SARS-CoV-2 Biology and COVID-19 Pathology.
Haas P; Muralidharan M; Krogan NJ; Kaake RM; Hüttenhain R
J Proteome Res; 2021 Feb; 20(2):1133-1152. PubMed ID: 33464917
[TBL] [Abstract][Full Text] [Related]
33. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
34. A network biology approach to identify crucial host targets for COVID-19.
Barman RK; Mukhopadhyay A; Maulik U; Das S
Methods; 2022 Jul; 203():108-115. PubMed ID: 35364279
[TBL] [Abstract][Full Text] [Related]
35. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
Low ZY; Yip AJW; Lal SK
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
[TBL] [Abstract][Full Text] [Related]
36. Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
Bhatt AN; Kumar A; Rai Y; Kumari N; Vedagiri D; Harshan KH; Chinnadurai V; Chandna S
Life Sci; 2022 Apr; 295():120411. PubMed ID: 35181310
[TBL] [Abstract][Full Text] [Related]
37. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
38. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.
Han N; Hwang W; Tzelepis K; Schmerer P; Yankova E; MacMahon M; Lei W; M Katritsis N; Liu A; Felgenhauer U; Schuldt A; Harris R; Chapman K; McCaughan F; Weber F; Kouzarides T
Sci Adv; 2021 Jun; 7(27):. PubMed ID: 34193418
[TBL] [Abstract][Full Text] [Related]
39. Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection.
Ciccosanti F; Di Rienzo M; Romagnoli A; Colavita F; Refolo G; Castilletti C; Agrati C; Brai A; Manetti F; Botta L; Capobianchi MR; Ippolito G; Piacentini M; Fimia GM
Antiviral Res; 2021 Jun; 190():105064. PubMed ID: 33781803
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.
Chakraborty C; Bhattacharya M; Mallick B; Sharma AR; Lee SS; Agoramoorthy G
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):225-238. PubMed ID: 33423554
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
